A crosstalk between hepcidin and IRE/IRP pathways controls ferroportin expression and determines serum iron levels in mice

  1. Edouard Charlebois
  2. Carine Fillebeen
  3. Angeliki Katsarou
  4. Aleksandr Rabinovich
  5. Kazimierz Wisniewski
  6. Vivek Venkataramani
  7. Bernhard Michalke
  8. Anastasia Velentza
  9. Kostas Pantopoulos  Is a corresponding author
  1. Lady Davis Institute for Medical Research, Jewish General Hospital and Department of Medicine, McGill University, Canada
  2. Ferring Research Institute Inc, United States
  3. Department of Medicine II, Hematology/Oncology, University Hospital Frankfurt, Germany
  4. Institute of Pathology, University Medical Center Göttingen (UMG), Germany
  5. Helmholtz Zentrum München GmbH – German Research Center for Environmental Health, Research Unit Analytical BioGeoChemistry, Germany
8 figures and 2 additional files

Figures

Dietary iron loading does not disrupt inflammatory hepcidin induction in LPS-treated wild type mice but blunts hepcidin-mediated hypoferremia.

Nine-week-old male mice (n=12–14 per group) were fed control diet or high-iron diet (HID) for 1 day, 1 week, or 5 weeks prior to sacrifice. Half of the mice were injected intraperitoneally with saline and the other half with 1 µg/g LPS 4 hr before sacrifice. Sera were collected by cardiac puncture and analyzed for: (A) iron, (B) transferrin saturation, (D) ferritin, and (E) hepcidin. Livers were dissected and processed for biochemical analysis of: (C) liver iron content (LIC) by the ferrozine assay and (F) Hamp mRNA by qPCR. The dotted line in (A) and (B) indicates baseline serum iron and transferrin saturation, respectively, from mice on control diet. Data (A–E) are presented as the mean ± SEM and in (F) as geometric mean ± SD. Statistically significant differences (p<0.05) over time compared to values from saline- or LPS-treated control mice are indicated by a or b, respectively.

Figure 2 with 1 supplement
Iron overload blunts hepcidin responsiveness to LPS-induced inflammation.

Four-week-old male wild type mice (n=12–14 per group) were placed on high-iron diet (HID) for 5 weeks. Conversely, age- and sex-matched isogenic Hjv-/- mice (n=12–14 per group) were placed on iron-deficient diet (IDD) for 5 weeks to prevent excessive iron overload. Other animals from both genotypes were kept on control diet. Half of the mice were injected with saline and the other half with 1 µg/g LPS; all animals were sacrificed 4 hr later. Sera were collected by cardiac puncture and analyzed for: (A) iron, (B) transferrin saturation, (C) non-transferrin bound iron (NTBI), and (F) hepcidin. Livers were dissected and processed for LIC quantification by the ferrozine assay (D) and for histological detection of iron deposits by Perls’ staining (E; magnification: 20 ×). Livers were also used for qPCR analysis of following mRNAs: (G) Hamp, (H) Id1, (I) Socs3, (J) Slc40a1(+IRE), (K) Slc40a1(-IRE), (L) Slc11a2, (M) Slc39a14, (N) Lcn2, and (O) Tfrc. The dotted line in (A) and (B) indicates baseline serum iron and transferrin saturation, respectively, of wild type mice on control diet. Values in (A) represent ratios of serum iron levels between untreated and LPS-treated mice. Data in (A–F) are presented as the mean ± SEM while in (G–O) are presented as geometric mean ± SD. Statistically significant differences (p<0.05) compared to values from saline- or LPS-treated wild type control mice are indicated by a or b, respectively.

Figure 2—figure supplement 1
Effects of dietary iron manipulations in hepatic and splenic iron of wild type and Hjv-/- mice.

(A) Liver and (B) spleen sections from mice described in Figure 2 were analyzed histologically for iron deposits by Perls staining (magnification: 10 ×). HID: high-iron diet; IDD: iron-deficient diet.

Figure 3 with 2 supplements
Effects of LPS on hepatic and splenic ferroportin of iron-manipulated wild type and Hjv-/- mice.

Livers and spleens from mice described in Figure 2 were dissected and processed for immunohistochemical and biochemical analysis of ferroportin. Immunohistochemical staining of ferroportin in liver (A) and spleen (C) sections (magnification for liver is 20 × and for spleen 5 ×). Western blot for ferroportin and β-actin in liver (B) and spleen (D) extracts from four representative mice in each condition. Blots were quantified by densitometry and ferroportin/β-actin ratios are shown on the right. Densitometric data are presented as the mean ± SEM. Statistically significant differences (p<0.05) compared to values from saline- or LPS-treated wild type control mice are indicated by a or b, respectively. Statistics in bold were performed using unpaired Student’s t test. HID: high-iron diet; IDD: iron-deficient diet.

Figure 3—source data 1

Western blot quantifications.

https://cdn.elifesciences.org/articles/81332/elife-81332-fig3-data1-v2.xlsx
Figure 3—source data 2

Raw unlabeled Western blot ferroportin Figure 3D (a).

https://cdn.elifesciences.org/articles/81332/elife-81332-fig3-data2-v2.jpg
Figure 3—source data 3

Raw unlabeled Western blot ferroportin Figure 3D (b).

https://cdn.elifesciences.org/articles/81332/elife-81332-fig3-data3-v2.jpg
Figure 3—source data 4

Raw unlabeled Western blot β-actin Figure 3D.

https://cdn.elifesciences.org/articles/81332/elife-81332-fig3-data4-v2.jpg
Figure 3—source data 5

Raw unlabeled Western blot β-actin Figure 3D (b).

https://cdn.elifesciences.org/articles/81332/elife-81332-fig3-data5-v2.jpg
Figure 3—source data 6

Raw unlabeled Western blot ferroportin Figure 3B (a).

https://cdn.elifesciences.org/articles/81332/elife-81332-fig3-data6-v2.jpg
Figure 3—source data 7

Raw unlabeled Western blot β-actin Figure 3B (a).

https://cdn.elifesciences.org/articles/81332/elife-81332-fig3-data7-v2.jpg
Figure 3—source data 8

Raw unlabeled Western blot ferroportin and β-actin Figure 3B (a).

https://cdn.elifesciences.org/articles/81332/elife-81332-fig3-data8-v2.jpg
Figure 3—source data 9

Raw unlabeled Western blot ferroportin Figure 3B (b).

https://cdn.elifesciences.org/articles/81332/elife-81332-fig3-data9-v2.jpg
Figure 3—source data 10

Raw unlabeled Western blot β-actin Figure 3B (b).

https://cdn.elifesciences.org/articles/81332/elife-81332-fig3-data10-v2.jpg
Figure 3—source data 11

Raw labeled Western blot β-actin Figure 3B (b).

https://cdn.elifesciences.org/articles/81332/elife-81332-fig3-data11-v2.bmp
Figure 3—source data 12

Raw labeled Western blot ferroportin Figure 3B (b).

https://cdn.elifesciences.org/articles/81332/elife-81332-fig3-data12-v2.bmp
Figure 3—source data 13

Raw labeled Western blot ferroportin and β-actin Figure 3B (a).

https://cdn.elifesciences.org/articles/81332/elife-81332-fig3-data13-v2.bmp
Figure 3—source data 14

Raw labeled Western blot ferroportin Figure 3B (a).

https://cdn.elifesciences.org/articles/81332/elife-81332-fig3-data14-v2.bmp
Figure 3—source data 15

Raw labeled Western blot β-actin Figure 3B (a).

https://cdn.elifesciences.org/articles/81332/elife-81332-fig3-data15-v2.bmp
Figure 3—source data 16

Raw labeled Western blot ferroportin Figure 3D (b).

https://cdn.elifesciences.org/articles/81332/elife-81332-fig3-data16-v2.bmp
Figure 3—source data 17

Raw labeled Western blot ferroportin Figure 3D (a).

https://cdn.elifesciences.org/articles/81332/elife-81332-fig3-data17-v2.bmp
Figure 3—source data 18

Raw labeled Western blot β-actin Figure 3D (b).

https://cdn.elifesciences.org/articles/81332/elife-81332-fig3-data18-v2.bmp
Figure 3—source data 19

Raw labeled Western blot β-actin Figure 3D (a).

https://cdn.elifesciences.org/articles/81332/elife-81332-fig3-data19-v2.bmp
Figure 3—figure supplement 1
Low magnification immunohistochemical images of ferroportin in liver sections of dietary iron-manipulated wild type and Hjv-/- mice following LPS treatment.

Liver sections from mice described in Figure 2 were used for immunohistochemical analysis of ferroportin (magnifications: 10 × and 5 ×). HID: high-iron diet; IDD: iron-deficient diet.

Figure 3—figure supplement 2
Low magnification immunohistochemical images of ferroportin in spleen sections of dietary iron-manipulated wild type and Hjv-/- mice following LPS treatment.

Spleen sections from mice described in Figure 2 were used for immunohistochemical analysis of ferroportin (magnification: 2 ×). HID: high-iron diet; IDD: iron-deficient diet.

Figure 4 with 3 supplements
Iron depletion of Hjv-/- mice improves the efficacy of synthetic hepcidin to promote hypoferremia.

Four-week-old wild type male mice (n=12–14 per group) were placed on HID for 5 weeks. Conversely, age- and sex-matched isogenic Hjv-/- mice (n=12–14 per group) were placed on IDD for 5 weeks to prevent excessive iron overload. Other animals from both genotypes were kept on standard diet. Half of the mice were injected every 2 hr for a total of 4 injections with saline, and the other half with 2.5 µg/g synthetic hepcidin. Sera were collected by cardiac puncture and analyzed for: (A) iron, (B) transferrin saturation, and (C) non-transferrin bound iron (NTBI). Livers and spleens were dissected and processed for analysis of: (D) liver iron content (LIC) and (E) splenic iron content (SIC) by the ferrozine assay. (F) qPCR analysis of liver Hamp mRNA. The dotted line in (A) and (B) indicates baseline serum iron and transferrin saturation, respectively, of wild type mice on control diet. Values in (A) represent ratios of serum iron levels between untreated and hepcidin-treated mice. Data in (A–E) are presented as the mean ± SEM and in (F) as geometric mean ± SD. Statistically significant differences (p<0.05) compared to values from saline- or hepcidin-treated wild type control mice are indicated by a or b, respectively. HID: high-iron diet; IDD: iron-deficient diet.

Figure 4—figure supplement 1
Perls staining for iron deposits in liver and spleen sections of dietary iron-manipulated wild type and Hjv-/- mice following treatment with synthetic hepcidin.

(A) Liver and (B) spleen sections from mice described in Figure 4 were stained with Perls Prussian blue (magnification: 10 ×). HID: high-iron diet; IDD: iron-deficient diet.

Figure 4—figure supplement 2
Western analysis of transferrin receptors (Tfr1 and Tfr2) of dietary iron-manipulated wild type and Hjv-/- mice following treatment with synthetic hepcidin.

Livers from mice described in Figure 4 were analyzed by Western blot for expression of Tfr1, Tfr2, and β-actin; a representative image (out of n=2 samples) is shown on the left. The blots were quantified by densitometry and Tfr1/β-actin or Tfr2/β-actin ratios are shown on the right. HID: high-iron diet; IDD: iron-deficient diet.

Figure 4—figure supplement 3
Effects of LPS treatment on expression of mRNAs encoding iron transport proteins and signaling endpoints in the liver of dietary iron-manipulated wild type and Hjv-/- mice.

Livers from mice described in Figure 4 were dissected and processed for qPCR analysis of mRNAs encoding iron transport proteins and signaling endpoints. (A) Slc40a1(+IRE), (B) Socs3, (C) Id1, (D) Bmp6, (E) Slc11a2, (F) Slc39a14, (G) Lcn2, and (H) Tfrc. All data are presented as the geometric mean ± SD. Statistically significant differences (p<0.05) compared to values from saline- or hepcidin-treated control mice are indicated by a or b, respectively. HID: high-iron diet; IDD: iron-deficient diet.

Figure 5 with 2 supplements
Effects of synthetic hepcidin on hepatic and splenic ferroportin of iron-manipulatedwild type and Hjv-/- mice.

Livers and spleens from mice described in Figure 4 were dissected and processed for immunohistochemical and biochemical analysis of ferroportin. Immunohistochemical staining of ferroportin in liver (A) and spleen (C) sections (magnification for liver is 20 × and for spleen 10 ×). Western blot for ferroportin and β-actin in liver (B) and spleen (D) extracts from four representative mice in each condition. Blots were quantified by densitometry and ferroportin/β-actin ratios are shown on the right. Densitometric data are presented as the mean ± SEM. Statistically significant differences (p<0.05) compared to values from saline- or hepcidin-treatedwild type control mice are indicated by a or b, respectively. HID: high-iron diet; IDD: iron-deficient diet.

Figure 5—source data 1

Western blot quantifications.

https://cdn.elifesciences.org/articles/81332/elife-81332-fig5-data1-v2.xlsx
Figure 5—source data 2

Raw unlabeled Western blot ferroportin Figure 5D (a).

https://cdn.elifesciences.org/articles/81332/elife-81332-fig5-data2-v2.jpg
Figure 5—source data 3

Raw unlabeled Western blot β-actin Figure 5D (a).

https://cdn.elifesciences.org/articles/81332/elife-81332-fig5-data3-v2.jpg
Figure 5—source data 4

Raw unlabeled Western blot ferroportin Figure 5B (a).

https://cdn.elifesciences.org/articles/81332/elife-81332-fig5-data4-v2.jpg
Figure 5—source data 5

Raw unlabeled Western blot ferroportin Figure 5B (b).

https://cdn.elifesciences.org/articles/81332/elife-81332-fig5-data5-v2.jpg
Figure 5—source data 6

Raw unlabeled Western blot ferroportin Figure 5D (b).

https://cdn.elifesciences.org/articles/81332/elife-81332-fig5-data6-v2.jpg
Figure 5—source data 7

Raw unlabeled Western blot.

https://cdn.elifesciences.org/articles/81332/elife-81332-fig5-data7-v2.jpg
Figure 5—source data 8

Raw unlabeled Western blot ferroportin Figure 5D (c).

https://cdn.elifesciences.org/articles/81332/elife-81332-fig5-data8-v2.jpg
Figure 5—source data 9

Raw unlabeled Western blot β-actin Figure 5D (c).

https://cdn.elifesciences.org/articles/81332/elife-81332-fig5-data9-v2.jpg
Figure 5—source data 10

Raw unlabeled Western blot β-actin Figure 5B (a).

https://cdn.elifesciences.org/articles/81332/elife-81332-fig5-data10-v2.jpg
Figure 5—source data 11

Raw unlabeled Western blot β-actin Figure 5B (b).

https://cdn.elifesciences.org/articles/81332/elife-81332-fig5-data11-v2.jpg
Figure 5—source data 12

Raw labeled Western blot β-actin Figure 5B (b).

https://cdn.elifesciences.org/articles/81332/elife-81332-fig5-data12-v2.bmp
Figure 5—source data 13

Raw labeled Western blot β-actin Figure 5B (a).

https://cdn.elifesciences.org/articles/81332/elife-81332-fig5-data13-v2.bmp
Figure 5—source data 14

Raw labeled Western blot ferroportin Figure 5B (b).

https://cdn.elifesciences.org/articles/81332/elife-81332-fig5-data14-v2.bmp
Figure 5—source data 15

Raw labeled Western blot ferroportin Figure 5B (a).

https://cdn.elifesciences.org/articles/81332/elife-81332-fig5-data15-v2.bmp
Figure 5—source data 16

Raw labeled Western blot β-actin Figure 5D (a).

https://cdn.elifesciences.org/articles/81332/elife-81332-fig5-data16-v2.bmp
Figure 5—source data 17

Raw labeled Western blot ferroportin Figure 5D (a).

https://cdn.elifesciences.org/articles/81332/elife-81332-fig5-data17-v2.bmp
Figure 5—source data 18

Raw labeled Western blot β-actin Figure 5D (c).

https://cdn.elifesciences.org/articles/81332/elife-81332-fig5-data18-v2.bmp
Figure 5—source data 19

Raw labeled Western blot ferroportin Figure 5D (c).

https://cdn.elifesciences.org/articles/81332/elife-81332-fig5-data19-v2.bmp
Figure 5—source data 20

Raw labeled Western blot β-actin Figure 5D (b).

https://cdn.elifesciences.org/articles/81332/elife-81332-fig5-data20-v2.bmp
Figure 5—source data 21

Raw labeled Western blot ferroportin Figure 5D (b).

https://cdn.elifesciences.org/articles/81332/elife-81332-fig5-data21-v2.bmp
Figure 5—source data 22

Raw labeled Western blot ferroportin and β-actin Figure 5D (a).

https://cdn.elifesciences.org/articles/81332/elife-81332-fig5-data22-v2.bmp
Figure 5—source data 23

Raw unlabeled Western blot ferroportin and β-actin Figure 5D (a).

https://cdn.elifesciences.org/articles/81332/elife-81332-fig5-data23-v2.jpg
Figure 5—figure supplement 1
Low magnification immunohistochemical images of ferroportin in liver sections of dietary iron-manipulated wild type and Hjv-/- mice following treatment with synthetic hepcidin.

Liver sections from mice described in Figure 4 were used for immunohistochemical analysis of ferroportin (magnifications: 10 × and 5 ×). HID: high-iron diet; IDD: iron-deficient diet.

Figure 5—figure supplement 2
Low magnification immunohistochemical images of ferroportin in spleen sections of dietary iron-manipulated wild type and Hjv-/- mice following treatment with synthetic hepcidin.

Spleen sections from mice described in Figure 4 were used for immunohistochemical analysis of ferroportin (magnification: 2 ×). HID: high-iron diet; IDD: iron-deficient diet.

Dietary iron manipulations trigger IRP responses in the liver and spleen, as well as in primary hepatocytes and non-parenchymal liver cells of wild type and Hjv-/- mice.

Whole liver (A), whole spleen (B), isolated hepatocytes (C) or isolated non-parenchymal liver cells (D) from the mice described in Figure 4 were analyzed for IRE-binding activity by EMSA with a 32P-labelled IRE probe in the absence (top) or presence (bottom) of 2% mercaptoethanol (2-ME). Two or three representative samples from each condition are shown. The positions of IRE/IRP1 and IRE/IRP2 complexes are indicated by arrows. Shorter and longer exposures of the autoradiograms are shown in the left and middle panels, respectively. Relative band intensities were quantified by densitometry and shown on the right panels. (E) Isolated hepatocytes and isolated non-parenchymal liver cells were analyzed by Western blotting for expression of ferroportin and β-actin. Blots were quantified by densitometry and ferroportin/β-actin ratios are shown on the right. Densitometric data are presented as the mean ± SEM. Statistically significant differences (p<0.05) in values from wild type mice on control diet are indicated by a, from wild type mice on HID by b, and from Hjv-/- mice on control diet by c. HID: high-iron diet; IDD: iron-deficient diet; IRE: iron-responsive element; IRP: iron regulatory protein; EMSA: electrophoretic mobility shift assay.

Figure 6—source data 1

EMSA quantification.

https://cdn.elifesciences.org/articles/81332/elife-81332-fig6-data1-v2.xlsx
Figure 6—source data 2

Western quantification.

https://cdn.elifesciences.org/articles/81332/elife-81332-fig6-data2-v2.xlsx
Figure 6—source data 3

Raw unlabeled liver EMSA long exposure Figure 6A.

https://cdn.elifesciences.org/articles/81332/elife-81332-fig6-data3-v2.jpg
Figure 6—source data 4

Raw unlabeled liver EMSA long exposure 2-ME Figure 6A.

https://cdn.elifesciences.org/articles/81332/elife-81332-fig6-data4-v2.jpg
Figure 6—source data 5

Raw unlabeled liver EMSA short exposure Figure 6A.

https://cdn.elifesciences.org/articles/81332/elife-81332-fig6-data5-v2.jpg
Figure 6—source data 6

Raw unlabeled liver EMSA short exposure 2-ME Figure 6A.

https://cdn.elifesciences.org/articles/81332/elife-81332-fig6-data6-v2.jpg
Figure 6—source data 7

Raw unlabeled spleen EMSA long exposure Figure 6B.

https://cdn.elifesciences.org/articles/81332/elife-81332-fig6-data7-v2.jpg
Figure 6—source data 8

Raw unlabeled spleen EMSA long exposure 2-ME Figure 6B.

https://cdn.elifesciences.org/articles/81332/elife-81332-fig6-data8-v2.jpg
Figure 6—source data 9

Raw unlabeled spleen EMSA short exposure Figure 6B.

https://cdn.elifesciences.org/articles/81332/elife-81332-fig6-data9-v2.jpg
Figure 6—source data 10

Raw unlabeled spleen EMSA short exposure BME Figure 6B.

https://cdn.elifesciences.org/articles/81332/elife-81332-fig6-data10-v2.jpg
Figure 6—source data 11

Raw unlabeled Western blot β-actin Figure 6E.

https://cdn.elifesciences.org/articles/81332/elife-81332-fig6-data11-v2.jpg
Figure 6—source data 12

Raw unlabeled Western blot ferroportin Figure 6E.

https://cdn.elifesciences.org/articles/81332/elife-81332-fig6-data12-v2.jpg
Figure 6—source data 13

Raw unlabeled hepatocytes EMSA short exposure Figure 6C.

https://cdn.elifesciences.org/articles/81332/elife-81332-fig6-data13-v2.jpg
Figure 6—source data 14

Raw unlabeled hepatocytes EMSA short exposure 2-ME Figure 6C.

https://cdn.elifesciences.org/articles/81332/elife-81332-fig6-data14-v2.jpg
Figure 6—source data 15

Raw unlabeled hepatocytes EMSA long exposure Figure 6C.

https://cdn.elifesciences.org/articles/81332/elife-81332-fig6-data15-v2.jpg
Figure 6—source data 16

Raw unlabeled hepatocytes EMSA long exposure 2-ME Figure 6C.

https://cdn.elifesciences.org/articles/81332/elife-81332-fig6-data16-v2.jpg
Figure 6—source data 17

Raw unlabeled non-parenchymal cells EMSA short exposure Figure 6D.

https://cdn.elifesciences.org/articles/81332/elife-81332-fig6-data17-v2.jpg
Figure 6—source data 18

Raw unlabeled non-parenchymal cells EMSA short exposure 2-ME Figure 6D.

https://cdn.elifesciences.org/articles/81332/elife-81332-fig6-data18-v2.jpg
Figure 6—source data 19

Raw unlabeled non-parenchymal cells EMSA long exposure Figure 6D.

https://cdn.elifesciences.org/articles/81332/elife-81332-fig6-data19-v2.jpg
Figure 6—source data 20

Raw unlabeled non-parenchymal cells EMSA long exposure 2-ME Figure 6D.

https://cdn.elifesciences.org/articles/81332/elife-81332-fig6-data20-v2.jpg
Figure 6—source data 21

Raw labeled liver EMSA long exposure Figure 6A.

https://cdn.elifesciences.org/articles/81332/elife-81332-fig6-data21-v2.bmp
Figure 6—source data 22

Raw labeled liver EMSA long exposure 2-ME Figure 6A.

https://cdn.elifesciences.org/articles/81332/elife-81332-fig6-data22-v2.bmp
Figure 6—source data 23

Raw labeled liver EMSA short exposure Figure 6A.

https://cdn.elifesciences.org/articles/81332/elife-81332-fig6-data23-v2.bmp
Figure 6—source data 24

Raw labeled liver EMSA short exposure 2-ME Figure 6A.

https://cdn.elifesciences.org/articles/81332/elife-81332-fig6-data24-v2.bmp
Figure 6—source data 25

Raw labeled spleen EMSA short exposure Figure 6B.

https://cdn.elifesciences.org/articles/81332/elife-81332-fig6-data25-v2.bmp
Figure 6—source data 26

Raw labeled spleen EMSA short exposure 2-ME Figure 6B.

https://cdn.elifesciences.org/articles/81332/elife-81332-fig6-data26-v2.bmp
Figure 6—source data 27

Raw labeled spleen EMSA long exposure Figure 6B.

https://cdn.elifesciences.org/articles/81332/elife-81332-fig6-data27-v2.bmp
Figure 6—source data 28

Raw labeled spleen EMSA long exposure 2-ME Figure 6B.

https://cdn.elifesciences.org/articles/81332/elife-81332-fig6-data28-v2.bmp
Figure 6—source data 29

Raw labeled hepatocytes EMSA short exposure Figure 6C.

https://cdn.elifesciences.org/articles/81332/elife-81332-fig6-data29-v2.bmp
Figure 6—source data 30

Raw labeled hepatocytes EMSA short exposure 2-ME Figure 6C.

https://cdn.elifesciences.org/articles/81332/elife-81332-fig6-data30-v2.bmp
Figure 6—source data 31

Raw labeled hepatocytes EMSA long exposure Figure 6C.

https://cdn.elifesciences.org/articles/81332/elife-81332-fig6-data31-v2.bmp
Figure 6—source data 32

Raw labeled hepatocytes EMSA long exposure 2-ME Figure 6C.

https://cdn.elifesciences.org/articles/81332/elife-81332-fig6-data32-v2.bmp
Figure 6—source data 33

Raw labeled non-parenchymal cells EMSA short exposure Figure 6D.

https://cdn.elifesciences.org/articles/81332/elife-81332-fig6-data33-v2.bmp
Figure 6—source data 34

Raw labeled non-parenchymal cells EMSA short exposure 2-ME Figure 6D.

https://cdn.elifesciences.org/articles/81332/elife-81332-fig6-data34-v2.bmp
Figure 6—source data 35

Raw labeled non-parenchymal cells EMSA long exposure Figure 6D.

https://cdn.elifesciences.org/articles/81332/elife-81332-fig6-data35-v2.bmp
Figure 6—source data 36

Raw labeled non-parenchymal cells EMSA long exposure 2-ME Figure 6D.

https://cdn.elifesciences.org/articles/81332/elife-81332-fig6-data36-v2.bmp
Figure 6—source data 37

Raw labeled Western blot ferroportin and β-actin Figure 6E.

https://cdn.elifesciences.org/articles/81332/elife-81332-fig6-data37-v2.bmp
Iron regulation of Slc40a1(+IRE) mRNA translation in the mouse liver.

Four-week-old wild type male mice (n=10–14 per group) were placed on high-iron diet (HID) for 5 weeks. Conversely, age- and sex-matched isogenic Hjv-/- mice (n=10–14 per group) were placed on iron-deficient diet (IDD) for 5 weeks to prevent excessive iron overload. Other animals from both genotypes were kept on control diet. At the endpoint, the mice were sacrificed, and livers were used for polysome profile analysis and iron assays. (A) Recording of absorbance at 254 nm of representative samples. Fraction numbers and direction of the gradient are indicated. (B–D) Liver polysome profiles from n=3 mice in each experimental group. Distribution of (B) Slc40a1(+IRE), (C) Fth1 and (D) Actb mRNAs among light monosomal and heavy polysomal fractions (separated by dashed line) was analyzed by qPCR. Bar graph comparisons of pooled fractions are shown on the right. Numbers indicate the fold change compared towild type mice oncontrol diet. (E and F) Analysis of total iron (E), and redox iron speciation (F) in the liver by CE-ICP-MS. Data are presented as the mean ± SEM. Statistical analysis in (A) was performed by two-way ANOVA and in (B, C) by one-way ANOVA. Statistically significant differences (p<0.05) compared to values from wild type mice on control are indicated by a.

Elimination of ferroportin mRNA by prolonged LPS treatment potentiates hepcidin-induced hypoferremia in mouse models of iron overload.

Four-week-old wild type male mice (n=10–14 per group) were placed on high-iron diet (HID) for 5 weeks. Conversely, age- and sex-matched isogenic Hjv-/- mice (n=10–14 per group) were placed on iron-deficient diet (IDD) for 5 weeks to prevent excessive iron overload. Other animals from both genotypes were kept on control diet. (A and B) Half of the mice were injected with saline and the other half with 1 µg/g LPS and sacrificed after 8 hr. Livers were dissected and processed for qPCR analysis of Slc40a1(+IRE) (A) and Slc40a1(-IRE) (B) mRNAs. (C–E) All mice were injected with 1 µg/g LPS. Half of the animals were subsequently injected with saline, and the other half with 2.5 µg/g synthetic hepcidin every 2 hr for a total of 4 injections. At the endpoint the mice were sacrificed. Sera were collected by cardiac puncture and analyzed for: (C) iron, (D) transferrin saturation, and (E) non-transferrin bound iron (NTBI). The dotted line in (C) and (D) indicates baseline serum iron and transferrin saturation, respectively, of wild type mice on control diet. Data are presented as (A–B) geometric mean ± SD or (C–E) mean ± SEM. Statistically significant differences (p<0.05) compared to values from saline-, LPS- or hepcidin-treated wild type mice on control diet are indicated by a, b or c, respectively.

Additional files

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Edouard Charlebois
  2. Carine Fillebeen
  3. Angeliki Katsarou
  4. Aleksandr Rabinovich
  5. Kazimierz Wisniewski
  6. Vivek Venkataramani
  7. Bernhard Michalke
  8. Anastasia Velentza
  9. Kostas Pantopoulos
(2022)
A crosstalk between hepcidin and IRE/IRP pathways controls ferroportin expression and determines serum iron levels in mice
eLife 11:e81332.
https://doi.org/10.7554/eLife.81332